We claim:

1. A method of inhibiting a drug resistant bacterial pathogen, comprising

selecting a drug resistant bacterial pathogen; and

contacting the bacterial pathogen with a composition comprising a therapeutically effective amount of MSM and a therapeutically effective amount of an agent that inhibits the drug-sensitive form of the drug resistant bacterial pathogen, thereby inhibiting a drug resistant bacterial pathogen.

2. A method of sensitizing a drug resistant bacterial pathogen to a drug the bacterial pathogen is resistant to, comprising

selecting a drug resistant bacterial pathogen; and

contacting the bacterial pathogen with a composition comprising a therapeutically effective amount of MSM, thereby sensitizing the drug resistant bacterial pathogen to the drug the bacterial pathogen is resistant to.

3. A method of inhibiting a drug-sensitive bacterial pathogen from developing drug resistance, comprising:

selecting a drug sensitive bacterial pathogen; and

contacting the drug-sensitive bacterial pathogen with a composition comprising a therapeutically effective amount of MSM and a therapeutically effective amount of an agent that inhibits the drug-sensitive bacterial pathogen, thereby inhibiting the drug-sensitive bacterial pathogen from developing drug resistance.

4. The method of claims 1 or 2, wherein the bacterial pathogen is MRSA.

5. The method of claim 3, wherein the bacterial pathogen is *Staphylococcus aureus*.

6. The method of claim 4, wherein the agent is a Beta-lactam antibiotic.

7. The method of claim 6, wherein the agent comprises penicillin derivatives, cephalosporins, penems, monobactams, carbapenems, Beta-lactamase inhibitors or a combination of two or more thereof.

8. The method of claim 6, wherein the agent comprises methicillin or oxacillin.

9. The method of any one of the previous claims, wherein the effective amount of MSM is about 5-20% MSM, about 5-16% MSM, about 5-10% MSM, about 5-8% MSM, about 9-16% MSM or about 10-15% MSM.

10. The method of any one of the previous claims, wherein the effective amount of MSM is about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 % MSM.

11. The method of any one of the previous claims, wherein the effective amount of MSM is about 5-10% MSM.

12. The method of any one of the previous claims, wherein the bacterial pathogen is on a surface.

13. The method of any one of the previous claims, wherein the bacterial pathogen is in a subject.

16. The method of any one of the previous claims, wherein the composition is administered topically.

14. The method of any one of the previous claims, wherein the composition is administered with an inhalant device.

15. The method of any one of the previous claims, wherein the bacterial pathogen is contacted with the composition for about 24, 36, 48, 60, 72, 84, 96, 108 or 120 hours.

16. The method of any one of the previous claims, wherein the composition comprises 0-5% sodium chloride.

CLAIMS

1. Use of a therapeutically effective amount of MSM and a therapeutically effective amount of an antibiotic that inhibits a drug-sensitive form of a drug-resistant bacterial pathogen in the manufacture of a medicament for inhibiting the drug-resistant bacterial pathogen.

2. Use of a therapeutically effective amount of MSM in the manufacture of a medicament for sensitizing a drug resistant bacterial pathogen to the drug to which the bacterial pathogen is resistant.

3. Use of a therapeutically effective amount of MSM and a therapeutically effective amount of an agent that inhibits a drug-sensitive bacterial pathogen in the manufacture of a medicament for inhibiting the drug-sensitive bacterial pathogen from developing drug resistance.

4. Use of a therapeutically effective amount of MSM in the manufacture of a medicament for inhibiting a drug-sensitive bacterial pathogen from developing drug resistance.

5. Use according to claim 1 or 2 wherein the bacterial pathogen is MRSA or use according to claim 3 or 4 wherein the bacterial pathogen is *Staphylococcus aureus*.